2 weeks Ago By ABMN Staff
Wolfe Research downgraded shares of Alnylam Pharmaceuticals ( NASDAQ:ALNY – Free Report ) from a peer perform rating to an underperform rating in a report released on Tuesday morning, Marketbeat Ratings reports. A number of other equities research analysts have also weighed in on ALNY. Canaccord Genuity Group lifted their price objective on shares of Alnylam Pharmaceuticals from $366.
00 to $384.00 and gave the company a “buy” rating in a report on Friday, November 1st. JPMorgan Chase & Co.
boosted their target price on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a research report on Monday, August 26th.
Chardan Capital reissued a “buy” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Raymond James boosted their target price on shares of Alnylam Pharmaceuticals from $275.
00 to $298.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. Finally, TD Cowen upped their price objective on shares of Alnylam Pharmaceuticals from $282.
00 to $371.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. One research analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have issued a buy rating to the company.
Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $294.50.
Read Our Latest Stock Analysis on ALNY Alnylam Pharmaceuticals Stock Performance Alnylam Pharmaceuticals ( NASDAQ:ALNY – Get Free Report ) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.
51) by ($0.36). The business had revenue of $500.
90 million for the quarter, compared to analyst estimates of $532.91 million. During the same period in the prior year, the firm earned $1.
15 earnings per share. The firm’s quarterly revenue was down 33.3% on a year-over-year basis.
As a group, sell-side analysts forecast that Alnylam Pharmaceuticals will post -2.22 earnings per share for the current fiscal year. Insider Transactions at Alnylam Pharmaceuticals In related news, CEO Yvonne Greenstreet sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th.
The shares were sold at an average price of $280.00, for a total value of $4,200,000.00.
Following the sale, the chief executive officer now owns 73,441 shares of the company’s stock, valued at $20,563,480. This trade represents a 16.96 % decrease in their ownership of the stock.
The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink . Corporate insiders own 1.50% of the company’s stock.
Institutional Trading of Alnylam Pharmaceuticals Hedge funds have recently added to or reduced their stakes in the company. Plato Investment Management Ltd raised its holdings in Alnylam Pharmaceuticals by 2,666.3% during the first quarter.
Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company’s stock worth $674,000 after purchasing an additional 4,346 shares in the last quarter. Diversified Trust Co acquired a new stake in Alnylam Pharmaceuticals during the second quarter worth approximately $1,210,000. Breakwater Capital Group purchased a new position in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $249,000.
Sanctuary Advisors LLC purchased a new position in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $578,000. Finally, Los Angeles Capital Management LLC grew its position in shares of Alnylam Pharmaceuticals by 11,433.4% during the third quarter.
Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after acquiring an additional 135,829 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.
Alnylam Pharmaceuticals Company Profile ( Get Free Report ) Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. Featured Articles Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
